Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 16, 2019

Study Completion Date

March 23, 2021

Conditions
Hormone Receptor Positive HER-2 Negative Breast Cancer
Interventions
DRUG

Palbociclib + Letrozole or Fulvestrant

Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months

Trial Locations (6)

19107

Thomas Jefferson University, Philadelphia

20007

MedStar Georgetown University Hospital, Washington D.C.

20013

MedStar Washington Hospital Center, Washington D.C.

21218

MedStar Union Memorial Hospital, Baltimore

21239

MedStar Good Samaritan Hospital, Baltimore

60637

University of Chicago, Chicago

All Listed Sponsors
collaborator

University of Chicago

OTHER

collaborator

Thomas Jefferson University

OTHER

lead

Georgetown University

OTHER

NCT02692755 - Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer | Biotech Hunter | Biotech Hunter